HIMS Stock Recent News
HIMS LATEST HEADLINES
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform committed to breaking down barriers to safe and affordable healthcare, today announced access to the most common compounded GLP-1 subscriptions for as low as $99 a month for eligible U.S. military, veterans, teachers, nurses and first responders. Providing access to safe, affordable weight loss solutions is more critical than ever yet many Americans do not have.
Buying a new pharmacy will allow Hims & Hers to expand into new markets.
This telemedicine company seems to leapfrog from one hot area in healthcare to another. Its strategy of acquiring members and turning them into paid subscribers is promising.
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $16.28, moving -1.75% from the previous trading session.
Hims & Hers' stock decline after GLP-1 concerns is an overreaction, presenting a strong investment opportunity. Management's consistent outperformance and strategic leadership, including key hires, bolster confidence in Hims' ability to scale and achieve ambitious targets. Exceptional revenue growth, healthy balance sheet, and a share buyback program highlights Hims' strong financial position.
Hims & Hers completed the acquisition of MedisourceRX, a pharmacy that will expand in-house production. The deal included issuing stock, which will ultimately dilute shareholders.
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
HIMS is enhancing its offerings and expanding the breadth of health and wellness products and services. However, macro challenges are likely to hurt its performance.
Ben Lichtenstein and Don Kaufman focus on finance and health in today's Big 3. They break down the technical trends for Hims & Hers (HIMS), the iShares 20+ Year Treasury Bond (TLT), and Wells Fargo (WFC).
Capitalizing on the popularity of weight-loss drugs like Wegovy and Zepbound, Hims & Hers Health (NYSE:HIMS) has exploited a loophole in Food & Drug Administration regulations to bring to market similar drugs without having to undergo the rigors of clinical testing the pharmaceutical giants are required to pursue.